Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Equillium, Inc./ 10-Q

Quarterly Report · 10-Q

Equillium, Inc.

EQNASDAQEQUITYCurrent

Quarterly Report

Filed Aug 13, 2026Accepted Aug 13, 2026, 4:15 PM EDTCIK 1746466Accession 0001193125-26-349235
View company →Permanent SEC source ↗
Share

Company context

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of several novel immunomodulatory assets and product platform targeting immuno-inflammatory pathways.

Current securities

EQNASDAQ · EQUITY · Current

Recent company filings

  1. SCHEDULE 13G filingAug 13, 2026
  2. Results of Operations and Financial ConditionAug 13, 2026
  3. 4 filingMay 29, 2026
  4. 4 filingMay 29, 2026
  5. 4 filingMay 29, 2026

As-filed source

Primary evidence
As filedOpen full document ↗